Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

Next Previous
X
Search
Trial Profile

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Aspirin
  • Indications Essential thrombocythaemia; Polycythaemia vera; Venous thrombosis
  • Focus Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 08 Dec 2020 Results of pooled analysis (of data from MPN-RC 111 and MPN-RC 112 studies) assessing the Symptom burden and quality of life in high-risk essential Thrombocythemia and Polycythemia Vera patients presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 Results assessing activity of pegylated interferon alfa-2a (PEG) in two trials (MPD-RC 111; NCT01259817 and MPD-RC 112; NCT01258856) released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results assessing MPN symptom impact and quality of life, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top